1.40
前日終値:
$1.41
開ける:
$1.44
24時間の取引高:
660.19K
Relative Volume:
0.71
時価総額:
$88.56M
収益:
$139.77M
当期純損益:
$-97.62M
株価収益率:
-0.8861
EPS:
-1.58
ネットキャッシュフロー:
$-61.71M
1週間 パフォーマンス:
+2.19%
1か月 パフォーマンス:
-4.76%
6か月 パフォーマンス:
-9.68%
1年 パフォーマンス:
-58.82%
Macrogenics Inc Stock (MGNX) Company Profile
名前
Macrogenics Inc
セクター
電話
301-251-5172
住所
9704 MEDICAL CENTER DRIVE, Rockville, MD
MGNX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
MGNX
Macrogenics Inc
|
1.40 | 89.19M | 139.77M | -97.62M | -61.71M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-17 | 再開されました | Barclays | Overweight |
| 2024-11-07 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-08-01 | ダウングレード | BTIG Research | Buy → Neutral |
| 2024-07-31 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2024-07-31 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-05-10 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-05-10 | ダウングレード | Stifel | Buy → Hold |
| 2024-05-10 | ダウングレード | TD Cowen | Buy → Hold |
| 2024-04-26 | 開始されました | B. Riley Securities | Buy |
| 2024-04-09 | アップグレード | TD Cowen | Hold → Buy |
| 2024-03-04 | 繰り返されました | BTIG Research | Buy |
| 2024-02-14 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-12-20 | アップグレード | Citigroup | Neutral → Buy |
| 2023-11-07 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-03-17 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-11-22 | ダウングレード | Cowen | Outperform → Market Perform |
| 2022-11-14 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2022-07-18 | ダウングレード | SMBC Nikko | Outperform → Neutral |
| 2022-07-11 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-05-04 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-02-28 | アップグレード | Citigroup | Neutral → Buy |
| 2022-02-11 | 開始されました | BMO Capital Markets | Outperform |
| 2022-02-04 | 開始されました | SMBC Nikko | Outperform |
| 2021-11-17 | 再開されました | Guggenheim | Buy |
| 2021-10-19 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-10-15 | 再開されました | BTIG Research | Buy |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-03-12 | アップグレード | Barclays | Underweight → Overweight |
| 2020-12-22 | 再開されました | H.C. Wainwright | Buy |
| 2020-08-03 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-06-01 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-05-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-04 | 開始されました | Barclays | Underweight |
| 2019-12-19 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-12-18 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-11-21 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2019-11-20 | 再開されました | Guggenheim | Neutral |
| 2019-05-03 | アップグレード | Wedbush | Neutral → Outperform |
| 2019-04-12 | 開始されました | Guggenheim | Neutral |
| 2019-02-07 | アップグレード | Citigroup | Sell → Buy |
| 2019-02-07 | ダウングレード | Wedbush | Outperform → Neutral |
| 2019-02-06 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2019-02-04 | ダウングレード | Citigroup | Neutral → Sell |
| 2018-12-10 | ダウングレード | Raymond James | Outperform → Underperform |
| 2018-09-10 | 再開されました | BTIG Research | Buy |
| 2018-05-31 | 開始されました | Evercore ISI | Outperform |
| 2018-03-05 | 開始されました | H.C. Wainwright | Buy |
| 2017-03-31 | 開始されました | Raymond James | Outperform |
すべてを表示
Macrogenics Inc (MGNX) 最新ニュース
Will MacroGenics Inc stock attract more institutional investorsRecession Risk & Real-Time Volume Triggers - moha.gov.vn
Reviewing MacroGenics (NASDAQ:MGNX) & Exagen (NASDAQ:XGN) - Defense World
Wall Street analysts’ outlook for Macrogenics Inc (MGNX) - setenews.com
What analysts say about MacroGenics Inc stockReal-Time Stock Alerts & Free Tremendous Portfolio Expansion - earlytimes.in
MacroGenics (NASDAQ:MGNX) Shares Cross Below 200-Day Moving AverageHere's What Happened - MarketBeat
MacroGenics (NASDAQ:MGNX) Shares Cross Below 200-Day Moving Average – Here’s What Happened - Defense World
IM Cannabis (NASDAQ:IMCC) & MacroGenics (NASDAQ:MGNX) Head to Head Survey - Defense World
Macrogenics (MGNX) Stock Analysis Report | Financials & Insights - Benzinga
MGNX (Macrogenics) EPS without NRI : $-1.20 (TTM As of Sep. 2025) - GuruFocus
MGNX (Macrogenics) Operating Cash Flow per Share : $-2.58 (TTM As of Sep. 2025) - GuruFocus
MacroGenics, Inc. (NASDAQ:MGNX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
MacroGenics, Inc. (NASDAQ:MGNX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference - Enidnews.com
Taking the lead: Macrogenics Inc (MGNX) - Setenews
Is MacroGenics Inc. stock cheap at current valuationEarnings Recap Summary & High Conviction Buy Zone Picks - newser.com
Is MacroGenics Inc. stock positioned for digital transformation2025 AllTime Highs & Daily Volume Surge Trade Alerts - newser.com
Will MacroGenics Inc. stock recover faster than peersForecast Cut & Free Growth Oriented Trading Recommendations - newser.com
MacroGenics Announces Departure of Chief Medical Officer - The Globe and Mail
Why MacroGenics Inc. stock attracts high net worth investorsGap Up & Weekly Setup with High ROI Potential - newser.com
Is MacroGenics Inc. stock attractive for passive investorsLong Setup & Expert Verified Movement Alerts - newser.com
Will MacroGenics Inc. stock continue dividend increasesEarnings Recap Report & Long-Term Safe Investment Plans - newser.com
What MACD and RSI say about MacroGenics Inc.2025 Year in Review & Risk Managed Investment Entry Signals - newser.com
Automated trading signals detected on MacroGenics Inc.Inflation Watch & Safe Entry Point Identification - newser.com
Ranking MacroGenics Inc. among high performing stocks via toolsSell Signal & Community Consensus Trade Alerts - newser.com
Will MacroGenics Inc. stock recover after recent drop2025 Technical Overview & Safe Capital Growth Tips - newser.com
Comparing MacroGenics Inc. in custom built stock radarsJuly 2025 Highlights & AI Forecast Swing Trade Picks - newser.com
United States Bispecific T-cell Engagers (BiTEs) Market Size, - openPR.com
Macrogenics Inc (MGNX) 財務データ
収益
当期純利益
現金流量
EPS
Macrogenics Inc (MGNX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| HEIDEN WILLIAM K | Director |
Aug 20 '25 |
Buy |
1.49 |
49,500 |
73,755 |
111,000 |
| Koenig Scott | Director |
Aug 13 '25 |
Option Exercise |
0.00 |
52,829 |
0 |
830,244 |
| Bonvini Ezio | Sr VP, Research & CSO |
Feb 15 '25 |
Option Exercise |
0.00 |
16,665 |
0 |
124,414 |
| Karrels James | SVP, CFO and Secretary |
Feb 15 '25 |
Option Exercise |
0.00 |
14,998 |
0 |
192,591 |
| Koenig Scott | President and CEO |
Feb 15 '25 |
Option Exercise |
0.00 |
42,329 |
0 |
777,415 |
| Peters Jeffrey Stuart | Senior VP and General Counsel |
Feb 15 '25 |
Option Exercise |
0.00 |
13,332 |
0 |
18,858 |
| Risser Eric Blasius | Chief Operating Officer |
Feb 15 '25 |
Option Exercise |
0.00 |
16,665 |
0 |
62,422 |
| Smith Beth Ann | VP, Controller & Treasurer |
Feb 15 '25 |
Option Exercise |
0.00 |
1,095 |
0 |
9,955 |
| Smith Beth Ann | VP, Controller & Treasurer |
Feb 15 '25 |
Sale |
2.56 |
423 |
1,083 |
9,532 |
| Spitznagel Thomas | Sr VP, Technical Ops |
Feb 15 '25 |
Option Exercise |
0.00 |
13,332 |
0 |
26,922 |
大文字化:
|
ボリューム (24 時間):